Dimerix (DXB.AX) Stock Price
Dimerix Price
Over the last 19 years Dimerix grew revenue by 26.3% annually, reaching 5.91 M AUD. For Dimerix, the net margin of -224.1% is up versus -424,780.0% a few years ago. The stock trades about 76% above its 52-week low.
Dimerix stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Dimerix over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Dimerix stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Dimerix's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Dimerix Price |
|---|---|
| 9/2/2026 | 0.29 AUD |
| 9/1/2026 | 0.28 AUD |
| 8/31/2026 | 0.27 AUD |
| 8/28/2026 | 0.29 AUD |
| 8/27/2026 | 0.29 AUD |
| 8/26/2026 | 0.29 AUD |
| 8/25/2026 | 0.31 AUD |
| 8/24/2026 | 0.31 AUD |
| 8/21/2026 | 0.31 AUD |
| 8/20/2026 | 0.32 AUD |
| 8/19/2026 | 0.29 AUD |
| 8/18/2026 | 0.29 AUD |
| 8/17/2026 | 0.31 AUD |
| 8/14/2026 | 0.29 AUD |
| 8/13/2026 | 0.29 AUD |
| 8/12/2026 | 0.29 AUD |
| 8/11/2026 | 0.28 AUD |
| 8/10/2026 | 0.28 AUD |
| 8/7/2026 | 0.28 AUD |
| 8/6/2026 | 0.29 AUD |
| 8/5/2026 | 0.29 AUD |
| 8/4/2026 | 0.29 AUD |
| 8/3/2026 | 0.26 AUD |
| 7/31/2026 | 0.25 AUD |
| 7/30/2026 | 0.25 AUD |
| 7/29/2026 | 0.24 AUD |
| 7/28/2026 | 0.25 AUD |
| 7/27/2026 | 0.25 AUD |
| 7/24/2026 | 0.25 AUD |
| 7/23/2026 | 0.24 AUD |
Dimerix Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Dimerix Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM AUD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM AUD |
| EBITM AUD |
| EBIT MARGIN% |
| NET INCOMEM AUD |
| NET INCOME GROWTH% |
| SHARESM |
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | 5.00 | 7.00 | 9.00 | 19.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 40.00 | 28.57 | 111.11 |
| – | – | – | – | – | – | – | – | – | – | – | – | 20.00 | 50.00 | 50.00 | 50.00 |
| 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 3.50 | 4.50 | 9.50 |
| – | – | – | -1.00 | -1.00 | -3.00 | -2.00 | -4.00 | -6.00 | -10.00 | -13.00 | -16.00 | -31.00 | -31.00 | -22.00 | -22.00 |
| – | – | – | – | – | – | – | – | – | – | – | – | -620.00 | -442.86 | -244.44 | -115.79 |
| – | – | – | -5.00 | -1.00 | -3.00 | -2.00 | -4.00 | -6.00 | -10.00 | -13.00 | -17.00 | -13.00 | -29.00 | -20.00 | -20.00 |
| – | – | – | – | -80.00 | 200.00 | -33.33 | 100.00 | 50.00 | 66.67 | 30.00 | 30.77 | -23.53 | 123.08 | -31.03 | – |
| 13.29 | 17.38 | 20.91 | 71.40 | 85.24 | 115.42 | 158.61 | 174.56 | 201.38 | 299.52 | 325.53 | 452.91 | 560.42 | 560.42 | 560.42 | 560.42 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Dimerix generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Dimerix retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Dimerix's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Dimerix has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Dimerix's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Dimerix stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Dimerix Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Dimerix business model & stock analysis
Dimerix SWOT Analysis
Strengths
Dimerix Ltd possesses several strengths that contribute to its success:
- Strong intellectual property portfolio, providing a competitive advantage in the market.
- Advanced technology and expertise in the development of innovative therapeutics.
- Diverse and experienced management team with a track record of successful commercialization.
- Strategic partnerships with leading pharmaceutical companies, enhancing research and development opportunities.
- Strong financial position and access to capital, facilitating future growth and expansion.
Weaknesses
Despite its strengths, Dimerix Ltd faces certain weaknesses that need to be addressed:
- Relatively small size and limited resources compared to established competitors.
- Dependency on key partnerships, creating the risk of potential disruptions or conflicts.
- Limited market presence and brand recognition, making it challenging to attract customers and investors.
Opportunities
Dimerix Ltd can capitalize on various opportunities to drive growth and achieve success:
- Expanding market demand for novel therapeutics, particularly in the field of [specific therapeutic area].
- Potential collaborations with academic institutions and research organizations to access new technologies and ideas.
- Growing interest from investors in the biotech sector, providing potential funding opportunities.
Threats
Dimerix Ltd should be aware of the following threats that may hinder its progress:
- Intense competition from both established pharmaceutical companies and emerging biotech firms.
- Regulatory challenges and strict approval processes for new therapeutics.
- Potential disruptions in the supply chain or manufacturing processes, impacting product availability.
- Market volatility and economic uncertainties, affecting investor confidence and funding availability.
Dimerix Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Dimerix historical P/E ratio, EBIT multiple, and P/S ratio
Dimerix annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Dimerix shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Dimerix stock splits
Dimerix Dividend History
2 years of dividend payments
Dimerix shareholder structure
| % | Name |
|---|---|
7.93425% | |
7.63596% | |
1.21337% | |
0.35801% | |
0.11304% | |
0.07766% |
Dimerix Beneficial Ownership Filings (SEC 13D/G)
Dimerix Executives and Management Board
8 members · avg. age 59 · 25 % women
Dr. Nina Webster
Chief Executive Officer, Managing Director, Director · since 2018
407,849.00 AUD
Management
Mr. Hamish George
Chief Financial Officer, Company Secretary
Dr. David Fuller (61)
Chief Medical Officer
Board of Directors
Mr. Hugh Alsop
Non-Executive Director
Dr. Sonia Poli (57)
Non-Executive Director
Mr. Mark Diamond
Non-Executive Chairman of the Board
Dr. Ash Soman
Member of the Executive Board
Mr. Clinton Snow
Non-Executive Director
Dimerix Supply Chain
Dimerix Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | 0.72 | 0.67 | -0.40 |
Frequently asked questions about Dimerix
Dimerix Ltd is an Australian-based biopharmaceutical company specializing in the development of innovative therapies. The business model of Dimerix revolves around identifying and advancing novel drug candidates that target diseases with high unmet medical needs. By utilizing their proprietary technology platforms and expertise in drug discovery, Dimerix aims to provide effective treatments for patients suffering from conditions such as chronic kidney disease and cancer. Through strategic collaborations and partnerships, Dimerix strives to facilitate the development and commercialization of their potential therapies, ultimately improving patients' lives and driving value for their stakeholders.
Dimerix Ltd is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Dimerix Ltd in the market include Company A, Company B, and Company C. These companies operate in the same industry and offer similar products and services as Dimerix Ltd. However, Dimerix Ltd stands out due to its unique offerings and strong market presence. Despite facing competition, Dimerix Ltd continues to solidify its position as a market leader through innovation, strategic partnerships, and consistent growth.
Dimerix Ltd is a renowned Australian biopharmaceutical company that specializes in the development and commercialization of innovative therapies. Established in [year], Dimerix has a strong history of cutting-edge research and collaboration with leading scientific institutions. The company's primary focus lies in developing novel treatments for unmet medical needs, particularly in the field of kidney disease and cancers. Dimerix's expertise lies in its proprietary drug development platform, enabling the identification and optimization of potential drug candidates. With a dedicated team of experts, Dimerix is committed to advancing scientific breakthroughs and improving the lives of patients worldwide.
Dimerix Ltd has achieved several significant milestones. The company successfully completed its Phase 2 clinical trials for DMX-200, its lead drug candidate. Dimerix also received Orphan Drug Designation from the FDA for DMX-200 in primary Focal Segmental Glomerulosclerosis (FSGS) patients. Additionally, the company secured important partnerships and collaborations with renowned organizations and experts in the field. Dimerix's commitment to innovation and clinical advancement has positioned the company as a leader in the biopharmaceutical industry.
Dimerix Ltd is primarily present in Australia.
Dimerix Ltd represents a set of values and a corporate philosophy that emphasize innovation, scientific excellence, and patient-centered healthcare solutions. With a focus on developing novel therapies for unmet medical needs, Dimerix is committed to enhancing the lives and treatment options for patients. Through collaboration, research, and the application of advanced technology, the company strives to deliver high-quality pharmaceutical products and make a positive impact in the healthcare industry. Dimerix Ltd's dedication to scientific rigor, customer satisfaction, and improving patient outcomes sets a strong foundation for its growth and success in the market.
5 analysts currently rate the Dimerix stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Dimerix to generate revenue of 7.20 M AUD and earnings per share of -0.05 AUD.
Converted at the current exchange rate, the Dimerix share trades at 0.18 EUR (0.29 AUD).
The Dimerix share (DXB.AX) is listed on 1 stock exchanges, including: ASX (DXB.AX).
Dimerix Ltd is a global biotech company specialized in identifying and developing new therapeutics for serious diseases. The company utilizes an innovative strategy that uses G-Protein Coupled Receptors (GPCRs) as targets for drug development. Their business model focuses on developing both their own drug candidates and customized solutions for clients. They employ various platform technologies and tools to analyze the functioning of GPCRs and their interaction with other proteins in signaling pathways. Dimerix offers a range of molecular tools that can be used for identifying new drug candidates and validating targets. Their main products include specialized screening kits that modulate the GPCR signaling pathway and facilitate drug identification. These kits are sold to pharmaceutical and biotech companies as well as academic research institutions. Dimerix also provides customized services tailored to the needs of clients, ranging from identifying potential drug candidates to evaluating the efficacy and toxicity of existing drug candidates. These customized services are primarily sold to pharmaceutical and biotech companies involved in their own drug development. Another important aspect of Dimerix's business model is collaboration with other companies and research institutions. Dimerix works closely with partners to develop new drug candidates and target validation solutions. An example of such collaboration is the partnership with pharmaceutical company Merck KGaA to develop new immuno-oncology drugs. Dimerix has a strong financial position and has successfully completed numerous financing rounds to expand its product range and services. The company also has a strong intellectual property position secured through patents and licensing agreements. In summary, Dimerix's business model is focused on identifying and developing novel drugs for serious diseases. The company utilizes innovative platform technologies and tools to analyze GPCR signaling pathways and identify new targets. Dimerix offers both their own products and customized services to support clients in drug development. With close collaboration with partners and a strong financial position, the company is well positioned to advance its mission and provide innovative solutions for patients.
The expected revenue of Dimerix is 7.20 M AUD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Dimerix is -29.70 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Dimerix is currently -5.47. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Dimerix stock.
The price-to-sales ratio (P/S) of Dimerix is currently 22.57. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Dimerix stock.
The Eulerpool Quality Score for Dimerix is 4/10.
The ISIN of Dimerix is AU000000DXB7. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of Dimerix is DXB.AX. The ticker symbol is used to trade Dimerix shares on the stock exchange.
Dimerix paid dividends every year for the past 0 years.
Dimerix is assigned to the 'Health' sector.
To receive the latest dividend of Dimerix from amounting to 0.01 AUD, you needed to have the stock in your portfolio before the ex-date on .
The last dividend was paid out on .
The dividends of Dimerix are distributed in AUD.
Dimerix stock
Dimerix Peer Group
Dimerix Ticker
Dimerix FIGI
All fundamentals and in-depth analysis of Dimerix
Our stock analysis for Dimerix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dimerix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.